About Merck
Merck is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by Merck Sharp & Dohme in January 2024. T-cell antibodies are developed against hematologic and solid tumor targets. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Merck has raised $130 million across 5 funding rounds from investors including UBS, New Leaf Venture Partners and Citadel. The company has 93 employees. Merck offers products and services including Medicines and Vaccines and Animal Health Products. Its focus areas include Pharmaceuticals and Biopharmaceuticals. Its legal entity is Merck & Co., Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Merck is established as a premier biopharmaceutical company focused on research and development. The company is engaged in creating innovative medicines and vaccines across various therapeutic areas including oncology, infectious diseases, and cardio-metabolic disorders. Solutions are developed through advanced data science, artificial intelligence, and sustainable science practices. Operations are conducted with a commitment to sustainability, aiming to benefit global communities. The companys efforts are directed towards addressing critical health challenges and improving patient outcomes worldwide.
- Headquarters Cambridge, United States
- Employees 93
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website harpoontx.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Merck Sharp & Dohme (Jan 2024)
- Legal Name Merck & Co., Inc.
- Total Equity Funding$130M (USD)
in 5 rounds
- Latest Funding Round$100.16M (USD), Post-IPO
Oct 2023
- InvestorsUBS
& 19 more
- Employee Count93
- Acquired byMerck Sharp & Dohme
(Jan 2024)
Products & Services of Merck
Merck offers a comprehensive portfolio of products and services, including Medicines and Vaccines and Animal Health Products.
Medicines and vaccines are developed for various diseases.
Products for animal health are offered globally.
Funding Insights of Merck
Merck has successfully raised a total of $130M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100.16 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130M
- Total Rounds 5
- Last Round Post-IPO — $100.16M
- First Round $15M
(Mar 2016)
- Investors Count 19
All 5 funding rounds of Merck with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $100.16M | Post-IPO | – | – | |
| Mar 2023 | $25M | Post-IPO | – | – | |
| Nov 2018 | $70M | Series C | – | Orbimed, Arix Bioscience | |
| Jun 2017 | $45M | Series B | – | Arix Bioscience, New Leaf Venture Partners | |
| Mar 2016 | $15M | Series A | – | MPM Capital | – |
20 investors in total: 20 institutional.
Investors in Merck
Merck has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include UBS, New Leaf Venture Partners and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| soleuscapital.com | ||||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Flexible, long-term financing solutions are provided to healthcare companies. | k2hv.com | Boston, United States | ||
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
| lionpoint.com | ||||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Taiho Ventures is focused on investing in global biotech ventures. | 2016 | taihoventures.com | Menlo Park, United States |
Investor details for Merck
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Merck
17 people are tracked at Merck (5 in leadership, 8 in board & advisors, 4 in team); the tracked headcount is 93.
| Name | Role | Group |
|---|---|---|
Luke Walker | Chief Medical Officer | Leadership |
Grace Wang | Director, TM Operations | Leadership |
Alpana Naresh | Executive Director, CMC Operations | Leadership |
Rick Austin | Vice President Research | Leadership |
Yu Ding | Associate Director | Leadership |
Ron Hunt | Director | Board & advisors |
Jeffrey Ravetch | Scientific Advisor | Board & advisors |
Charles Rudin | Scientific Advisor | Board & advisors |
Jonathan Drachman | Director | Board & advisors |
Andrew Robbins | Director | Board & advisors |
Joseph S. Bailes | Director | Board & advisors |
Ramy Ibrahim | Scientific Advisor | Board & advisors |
Mark Chin | Director | Board & advisors |
Phoebe Chua | Senior Manager, CMC Operations | Team |
Banmeet Anand | SVP, Translational Medicine | Team |
Chen Fang | Senior Scientist, Protein Analytics and Formulation Development | Team |
Julia Bushkov | HR Consultant | Team |
Complete people profiles for Merck
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Merck
5 dated milestones of Merck across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Merck is founded.
- Funding First funding round of $15.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.2M.
- Exit Acquired by Merck Sharp & Dohme.
Competitors of Merck
Merck has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Merck
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Merck (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Merck
Complete news archive for Merck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merck
Merck was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Merck is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Merck is a funded company, having raised a total of $130M across 5 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Mar 2016.
Merck has 93 employees.
Merck is established as a premier biopharmaceutical company focused on research and development. The company is engaged in creating innovative medicines and vaccines across various therapeutic areas including oncology, infectious diseases, and cardio-metabolic disorders. Solutions are developed through advanced data science, artificial intelligence, and sustainable science practices. Operations are conducted with a commitment to sustainability, aiming to benefit global communities. The companys efforts are directed towards addressing critical health challenges and improving patient outcomes worldwide.
Merck's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Merck offers Medicines and Vaccines and Animal Health Products.
Merck has 20 investors. Key investors include UBS, New Leaf Venture Partners, Citadel, Orbimed, and RA Capital.
Merck operates through Merck & Co., Inc..
Yes. Merck was acquired by Merck Sharp & Dohme in January 2024.